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The  synthetic  random  terpolymer (Glu ~°  Aia 3°  Tyrl°)n  (GAT) 1 elicits,  in  a 
number of inbred strains of mice, anti-GAT antibodies that can be characterized 
by various idiotypic specificities. Most anti-GAT antibodies express the so-called 
CGAT  (1) or pGAT (2) public idiotypic specificities, which correlate  with the 
recognition of Glu-Tyr-containing epitopes (3).  They require  both the heavy 
(H) and light (L) chains of the idiotype in order to be expressed (4).  Analysis of 
monoclonal  antibodies  allowed  the  definition,  within  the  CGAT-  anti-GAT 
antibodies, of a  new family of idiotypic determinants. They are also found in 
several  anti-GA  antibodies  and  are  therefore  termed  GA-1  specificities  (5). 
Finally, a  third group of anti-GAT antibodies expressed neither the CGAT (or 
pGAT) nor the GA-1 idiotopes. Isolation of a collection ofanti-GAT monoclonal 
antibodies from BALB/c, DBA/2, or C57BL/6 origin made it possible to study 
the VH and VL anti-GAT repertoire  in the different strains and to search for 
idiotypic structural correlates. 
An NH2-terminal  amino acid sequence of 16 Vn-VL pairs has been recently 
reported (6), leading to the proposals that both the CGAT (or pGAT) and the 
GA-1  idiotypes represented  the  expression  of a  pauci-gene system. The anti- 
GAT,CGAT + and the anti-GAT,GA-1 + antibodies use VH regions that may use 
the same germline gene(s), whereas these two types of antibodies express discrete 
sets of V, chains. The complete sequences of four BALB/c (7) and one C57BL/ 
6 (8) anti-GAT VH regions have been recently determined. We report here on 
the complete sequence of eight CGAT + anti-GAT monoclonal K chain variable 
regions. The experimental approach combined amino acid sequencing with an 
analysis of the nucleotide sequence (7),  using mRNA as a  template, a  synthetic 
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toin; SDS, sodium dodecyl sulfate. 
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oligonucleotide  as  a  primer,  and  a  modification  (9)  of the  chain  terminator 
method of DNA sequencing (10). 
Materials and Methods 
Hybridoma and Anti-GAT Monoclonal Antibodies.  The eight monoclonal antibodies were 
isolated from seven distinct series of hybridoma lines. Experimental conditions have been 
given previously in detail. The G5, G6 (11), and F 17 (12) series were derived from fusion 
with the NS1  cell line, whereas G7, G8 (11), H51, and H56 (6) were obtained with the 
X63  Ag8.653  (13)  myeloma  cell  line.  Characterization  of idiotypic specificities was 
reported earlier (6,  11). The hybridoma cells were transplanted into BALB/c mice or 
appropriate F~ hybrids and the resulting solid tumors were removed and stored at -70 °C. 
The corresponding anti-GAT monoclonal antibodies were specifically isolated from ascitic 
fluids on a GAT-amino-hexyl Sepharose column, as previously reported (12). 
Preparation  of Peptides from the L  Chains.  A combination of cleavage at tryptophanyl 
and glutamyl residues was used to isolate a peptide encompassing residues 36-105 (Kabat 
numbering; see reference 14) according to Lazure et al.  (15) with slight modifications. 
Mildly reduced and alkylated L chains (10 mg/ml) were dissolved in 0.05 M ammonium 
bicarbonate-0.2%  sodium  dodecyi sulfate  (SDS),  and  digested  with  V8  streptococcus 
protease (16), using an enzyme/substrate ratio of 1:25 (wt/wt). Incubation proceeded for 
24 h at 37°C. The digest was then transferred into dialysis tubing (benzoylated dialysis 
tubing; Sigma Chemical Co., St. Louis, MO), that retains molecules with a molecular mass 
>2,000 D. After exhaustive dialysis against a 0.15 M Tris-HCl, 2.10  -3 M EDTA, pH 8.2 
buffer, the sample was made 5 M in guanidine HCI, 0.15 M Tris HCI, 2.10  -8 M EDTA, 
pH 8.2, fully reduced with 20 mM iodoacetic acid, and dialyzed against 0.05 M ammonium 
bicarbonate. The precipitate that formed was redissolved in 0.3 M triethylammonium, 
succinylated (17),  and  dialyzed against  0.1  M  acetic acid.  The materials  were  passed 
through a  TSK SW  2000  high  performance liquid  chromatography (HPLC) column 
(Beckman Instruments, Inc., Fullerton, CA) equilibrated in 5 M guanidine HCI, 0.1  M 
acetic acid. The fraction corresponding to the 11,000 D size was made 80% in acetic acid 
and treated with an equal weight of iodosobenzoic acid. Incubation proceeded for 3 h at 
room temperature, in the dark, such that tryptophanyl-X peptide bonds were selectively 
cleaved (15). After dialysis against 0.1  M ammonium bicarbonate, the recovered material 
was lyophilized, then subjected immediately to amino acid sequencing. 
Protein Sequencing.  NH~-terminal amino acid sequences were determined in a Beckman 
890 C automatic sequencer, using program No. 122974 operated with 0.3 M Quadrol in 
the presence of polybrene (Aldrich Europe) (18).  The succinylated, iodosobenzoic acid 
(IBA) cleaved fragments were sequenced using the same conditions, except that the glycyl- 
glycine dipeptide was added to the polybrene (19).  Phenylthiohydantoin (PTH) amino 
acid derivatives were identified by HPLC, using a C  18 micro-Bondapack column and a 
Waters apparatus equipped with an automatic injector (WISP; Waters, Paris, France). An 
aliquot of each PTH derivative was hydrolyzed with iodohydric acid (20) and the resulting 
amino acid was identified on a  121 M Beckman amino acid analyzer. 
RNA Purification and Nucleotide Sequencing.  The RNA were extracted directly from the 
frozen tumors by the LiCl-urea method (21), selected for the poly(A)+-containing fraction 
on an oligo dT-celluiose column, and enriched for the L-coding mRNA by ultracentrifu- 
gation on a sucrose gradient (5-20%).  Nucleotide sequences were determined towards 
the 5' end of the mRNA, according to a modification of the original chain terminator 
method (10),  using the  mRNA  as a  template (9) and a  synthetic oligonucleotide as a 
primer for the reverse transcriptase (obtained from Dr.  Beard,  Life Science, Inc.,  St. 
Petersburg, FLA). This oligonucleotide had a sequence d(GTAGAAGGGTGGTAGGT) 
complementary to an mRNA segment of the 5' end of the C, region (Ser 116-Ser 122). 
It had been synthesized according to Gait et al. (22) and was a generous gift from Dr. C. 
Milstein.  2 ~g of mRNA and  10 ng of oligonucleotide primer were used per sequence. 
To minimize possible ambiguities in sequence determination on gels (9),  labeling with 
each of the three ot-32P deoxynucleotides (dCTP, dATP, and dGTP) was performed in 
separate experiments and each repeated at least twice. TONNELLE  ET  AL.  1417 
Results 
Hybridomas and Monoclonal Antibodies.  Main features of the eight hybridomas 
and their corresponding monoclonal antibodies are given in Table I. All anti- 
bodies were raised against the random terpolymer GAT. The five hybridomas 
of the G  series  were derived from  BALB/c  whereas H56  was derived from 
DBA/2  mice. The  F17  and  H51  hybridomas were prepared from F1  hybrid 
mice (C57BL/6 × DBA/2 and BALB/c × DBA/2, respectively), and it was thus 
not possible to determine the exact genetic origin of the isolated monoclonal 
chains, except for the F 17 71 chains, which were shown to be of C57BL/6 origin 
(8). 
General Strategy  for Sequence Determination.  The sequencing strategy, based on 
a combination of  amino acid and nucleotide sequence, using mRNA as a template, 
is outlined in  Fig.  1.  NH2-terminal sequences were already reported for most 
chains (6) with the exception of F17. On average, the first 43 amino acid residues 
were identified. The sequence of the G6 ~ chains was reinvestigated up to residue 
44. Nucleotide sequencing, which proceeded from the beginning of the constant 
region, was allowed to reach, in four cases, codon 35 (G8C, G8A, G7, and G6), 
providing therefore a large overlap with the NH~-terminal amino acid sequence. 
Furthermore, an overlap with the nucleotide sequence for the remaining chains 
and confirmation for the G7 and G8  A  chains were obtained by sequencing a 
peptide (starting at residue 36;  Kabat numbering) that had been isolated by a 
two-step hydrolysis with V8 staphylococcal protease and IBA. Finally, the com- 
plete amino acid sequence was derived for the eight ~ chains, from residue 1 to 
118, thus encompassing the complete V segments, J segments, and the beginning 
of the constant region. 
Isolation of the "V8-IBA" Peptides.  The combination of hydrolysis by V8 pro- 
tease with cleavage by IBA, under conditions defined by Lazure et al. (15), leads 
TABLE  I 
Characteristic Features of  Hybridoma and Hybridoma Products 
Nomenclature 
Abbrevia-  Full name  tion 
Public 
idiotypic 
Myeioma cell  Anti-  specifici-  Refer- 
line used for  Mouse strain  body  ties 
fusion  isotypes  (CGAT  ences 
or 
pGAT)* 
G5 Bb 2.2  G5  NSI  BALB/c  3,Ix  +  2, 3, 11 
G6 Bd 2.6  G6  NSI  BALB/c  3,1K  =1=  2, 3, 11 
G7 Ab 2.9  G7  X63 Ag8.653  BALB/c  ~,1~  +  2, 3, 11 
G8 Ca 1.7  G8C  X63 Ag8.653  BALB/c  "rlx  +  2, 3, 11 
G8 Ad 3.8  G8A  X63 Ag8.653  BALB/c  3'lx  +  2, 3, 11 
F17.170.2  FI7  NS1  C57BL]6 x  DBA/2  3"lx  +  12, 11 
H51.5.2  H51  X63 Ag8.653  BALB/c X DBA/2  3,1K  +  6 
H56.406.48  H56  X63 Ag8.653  DBA/2  #x  +  6 
* CGAT and pGAT idiotypic specificities may be considered very similar if not identical (11).  The 
CGAT specificities were detected using a guinea pig antiserum against D I-LP anti-GAT antibodies 
(1), whereas the pGAT specificities were identified by a rabbit antiserum directed against BALB/c 
polyclonal anti-GAT antibodies (2, 3). 1418  V,-GAT GENE FAMILY 
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FIGURE  1.  General strategy used for sequence determination. Amino acid sequences were 
determined from the NH2-terminus (~) or from residue 36 (--,) on a peptide (36-105) that 
was isolated by the combination of hydrolysis by V8 protease (at Trp 35) and cleavage with 
IBA (at Glu 105) (see Materials and Methods). Nucleotide sequencing (~----) was performed 
from the other end, using mRNA enriched for the x chain-coding fraction as a template and 
a synthetic oligonucleotide complementary to codons 116-192 (close to the beginning of the 
C, region) as a primer, according to the modification (9) of the chain terminator method (10). 
Numbering is that of Kabat et al. (14). 
to the isolation of a  large peptide extending from residue 36 to  105.  Cleavage 
with V8 protease occurs at glutamic acid residue 105, with an efficiency averaging 
50%.  After complete reduction and alkylation, both the released peptides and 
the  uncleaved  ~  chains  were  precipitated.  Solubilization  was  obtained  upon 
succinylation, a  treatment that also blocks the K-NH2 terminus. A  peptide, with 
a  molecular mass  of ~  11,000  D,  was  isolated with  HPLC  using an  SW  2000 
column. This material was treated with IBA, which selectively cleaves the peptide 
bond involving the unique tryptophanyl residue at position 35 with an efficiency 
of 50-60%. An additional peptide, obtained for the H51 L chain due to an extra 
Trp residue at position  95,  was lost upon dialysis.  The peptide beginning with 
tyrosyl  36  was  directly sequenced  without  further separation,  since  the  NH2- 
terminal peptide was succinylated. The number of amino acid residues that were 
successfully identified was  largely dependent upon the amount of peptide that 
was submitted to automatic sequencing, ranging from 13 residues with 20 nmol 
of G5 to 45 positions with 80 nmol of H51. 
mRNA  Sequencing.  The  chain  terminator  method  (10),  as  applied  to  the 
mRNA  templates (9), allowed  us to identify between  160 (H51  and  H56) and 
250 (most chains of the G series) nucleotides. Surprisingly, almost no background 
was  seen,  due  to the  possible  presence of MOPC-21  V~ in  mRNA  in  samples 
isolated from G5, G6, and F17, for which the NS-1 cell line was used for fusion. TONNELLE  ET  AL.  1419 
Very few ambiguous positions (8, ~ 0.5 %) remained after three separate analyses, 
using either of the three a-S2P-deoxynucleotides (dCTP, dATP, or dGTP; see 
Materials and Methods). 
Complete Sequence of Eight GAT-specific V, Chains.  Nucleotide and amino acid 
sequence data are given in Fig. 2.  It can be observed that for all but one of the 
134 amino acid/codon positions that have been determined by both methods, 
there is a complete agreement between results derived from mRNA and those 
obtained by protein sequencing. The only discrepancy concerned position 50 of 
the F 17 K  chain, for which a lysyl residue was identified as its succinyl derivative, 
using protein sequencing, whereas codon AGG (arginyl) was consistently deter- 
mined upon mRNA sequencing. 
Organization  of the  Diversity on  the  V,  Gene-encoded Section.  As  pointed  out 
previously (6), the eight L chains are highly homologous with respect to their 
NH2-terminal amino acid sequences (Fig.  2).  They clearly belong to the same 
subgroup (VK-1) as that defined by Potter et al. (23). However, considering that 
multiple identical substitutions at one given position may witness the expression 
of a discrete germline gene, it may be that the eight sequences fall into at least 
two families: One, represented by BALB/c K chains G8C, G5, and G7 may be 
defined by residues Ile (27 b), Tyr (34), and Arg (50), whereas the second one, 
composed of the F17, H51, and H56 chains, expresses alternative residues Leu 
(27 b), His (34), Lys (50), and Leu (83). An additional variability is superimposed 
on this polymorphism but appears unevenly distributed along the V region (Fig. 
3). One amino acid substitution was observed in FR1,  5 in CDR1, but none in 
FR2 or in CDR2, whereas fourteen substitutions were identified in FR3 and 13 
in CDR3. Therefore, out of 33 amino acid substitutions,  27 were located after 
position 65. Interestingly, the overall pattern looks quite different if one consid- 
ers  silent  nucleotide substitutions,  although  this  information was  only partial 
since mRNA sequencing did not cover the beginning of the chains. In fact, very 
few silent nucleotide substitutions were identified except for F17,  which con- 
tained 18 such differences that appeared scattered all along the variable region. 
JK Segments and the v-J and J-C Joining.  Three J~ segments were identified in 
the eight anti-GAT K  chains, although unevenly represented. G8A usedJK5, H51 
contained  JK 1, and all other chains expressed J~2. Alternative v-J rearrangements 
yielded four discrete amino acids at position 96 (Fig. 4), in agreement with other 
systems (24, 25). It may be noted that four BALB/c chains, G8C, G5, G6, and 
G7  used the same rearrangement, leading to  a  histidyl residue. The junction 
between J,  and  C,  was  such  that  the  first two  bases  of the arginyl codon at 
position  108  derived from J, whereas the third base  (G) pertained to the last 
residue of the 5' "flanking" region of C~. This situation is similar to that reported 
for the MOPC-21  K chain (9). 
Discussion 
Most GAT-specific murine antibodies (i.e., ---70-80%) express a major public 
idiotype, CGAT (1) or pGAT (2). Since it was previously shown that the presence 
of both the H  and the L  chains of the idiotype was required for these public 
specificities to be  expressed (4),  we have analyzed a  collection of monoclonal 
anti-GAT antibodies derived from different strains of mice to look for structural 1420 
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FIGURE  2.  Combined  amino  acid  and  nucleotide  sequences of eight anti-GAT,  CGAT +, 
monoclonal V. chains. Chains of the G  series were derived  from BALB/c  immunized mice; 
H56.406.48 was derived from DBA/2,  F17  from (C57BL/6  x  DBA/2)FI  hybrids, and H51 
from (BALB/c x  DBA/2)Fj  hybrids. Vertical lines indicate v.-J, and J,-C.joinings. TONNELLE ET  AL.  1421 
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FIGURE 3.  (Top)  Schematic representation of differences between the L anti-GAT, CGAT  + 
V, chains. Thin bars indicate silent nucleotide substitutions; thick bars indicate amino acid 
changes. (&) Positions of suggested germline polymorphism. (Bottom) Overall computation of 
silent (©) and amino acid substitution positions (Q). Numbering according to Kabat et al. (14). 
correlates of idiotypy in this system. This detailed analysis also provides insight 
into the origin of antibody diversity. 
In previous reports (6, 8), we presented evidence that the CGAT (or pGAT) 
GAT-specific antibodies used a very limited number of germ line genes for the 
expression of both the H  and the L chains. The determination of the complete 
amino acid and/or nucleotide sequence of eight V~ GAT-specific monoclonal 
chains reported in this paper fully substantiates these proposals. 
Origin of the Diversity in the V~ GAT-specific L Chains.  Comparison of the eight 
V~  amino  acid  sequences,  as  determined  directly  by  protein  sequencing  or 
indirectly from the mRNA nucleotide sequences, is shown in Fig. 5. Two groups 
of sequences  may  be  easily  distinguished,  on  the  basis  of alternate  multiple 1422  VrGAT  GENE  FAMILY 
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FIGURE 4.  Amino acids  identified at  position  96  resulting  from various  modalities  in  the 
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FIGURE  5.  Amino  acid sequence  of the eight anti-GAT, CGAT monoclonal V, chains,  as 
compared with the NZB myeloma L  chain 2205 (15),  BALB/c TEPC-105 (15),  and partial 
sequence of the BALB/c SAMM L chain (26).  The three chains included for comparison all 
pertain to the V.I  subgroup (23). 
repeats at positions 27  b (Ile/Leu),  34  (Tyr/His),  and 50  (Arg/Lys).  The  first 
group contains  four BALB/c  sequences  (G8C,  G5,  G6,  and  G7).  The  second 
group,  composed  of the  F17,  H56,  and  H51  chains,  expresses  in  addition  a 
characteristic Leu at position 83. The alternate multiple repeats may be consid- 
ered hallmarks of two discrete germline genes. Whether these two genes repre- 
sent allelic forms, one being expressed in the BALB/c  strain (G series) and the 
other in DBA/2 (H56 chain), cannot be distinguished because the two remaining 
chains, F 17 and H51, were derived from (C57BL/6  ×  DBA/2) and (BALB/c × 
DBA/2)FI hybrid mice, respectively. In addition, all sequences clearly pertain to 
the V,1 subgroup (23), but, within this family, the four BALB/c representatives 
(G8C, G5, G6, G7) were closely related to an NZB myeloma sequence (protein 
2205;  reference  15),  whereas  the second  set (F17,  H51,  H56)  was  extremely 
homologous to TEPC-105,  a  BALB/c  myeloma chain (15). Since the H56 was 
derived  from a  DBA/2  mouse,  it might  suggest  that DBA/2,  BALB/c,  NZB, 
and  possibly  C57BL/6  strains  possess  the  same  germline  gene  repertoire,  al- 
though  each  strain  may  use  different  V~  gene  subsets  to  produce  anti-GAT 
antibodies.  Finally, one V~ sequence, of BALB/c origin (G8A), was found to be 
extremely homologous to the BALB/c "SAMM" (26) myeloma L chain and may TONNELLE  ET  AL.  1423 
represent the expression of a third V~ gene, characterized by a leucyl residue at 
position 3 and a glutamyl at position 34. Since the SAMM protein was sequenced 
only as far as residue 35, it cannot be decided whether Lys (50) and Leu (83) 
may also be regarded as characteristic residues of this possibly third germline 
gene, or whether they might have arisen upon  conversion (27,  28)  from the 
TEPC-105 prototype. 
We reported earlier, based on NH2-terminal amino acid sequences, that the 
GAT-specific  V,  chains  were  extremely conserved.  Now  that  the  complete 
sequences are determined, the same conclusion holds true, except that a cluster 
of amino acid substitutions was clearly apparent between residues 83  and 93, 
i.e.,  at  the  end  of the  third  framework and  third  hypervariable regions.  By 
contrast, only one substitution occurred in FR1, none in FR2 or CDR2, and five 
in CDR 1. This clustering of variations, which seems superimposed on the germ- 
line patterns described above, is not found in other systems such as arsonate (29), 
galactane (30), or inulin (31) antibodies. A detailed comparison of the location 
of substitutions is given in Fig. 6. A similar observation was made for the GAT- 
specific VH  regions (8).  It  seems worth  noting that  two of the  L  chains that 
presented maximal substitutions in the FR3/CDR3  area (G8A and F17) were 
associated with H chains that possessed the highest diversity in the corresponding 
region  (G8A  [7],  F17  [8]).  This  would  suggest  that  various  combinations  of 
variable stretches of both the H  and the L chains in the V-D-J and V-J joining 
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FIGURE 6.  Computation of variable positions within each of the three V, chain systems: GAT 
(this paper), arsonate (Ars [29]), and galactane (Gal [30]). Variability is expressed according to 
the method defined by Wu and Kabat (32).  Numbers of chains compared were 8, 8, and 16 
for GAT, Ars, and Gal, respectively. Probable germline polymorphism is indicated (&) for the 
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areas  might result in  similarly interacting structures at  the combining site.  It 
should also be emphasized that both germline polymorphism and somatic varia- 
tions are presumably superimposed in Fig. 6 (top), and thus amplify the diversity 
pattern as compared with those obtained for the galactane and arsonate systems. 
Furthermore, the overall diversity that was observed within the antibodies of the 
GAT  system  may also  result  from  the  higher  heterogeneity of the  random 
copolymer, as compared with the dominant epitopes of the galactane and arsonate 
antigens. 
Silent nucleotide substitutions were found almost exclusively in the F17 chain 
(Fig. 3). If these differences were proven to be of germline origin, it would force 
the conclusion that F17 expresses a C57BL/6 chain, different from the BALB/ 
c and DBA/2 structures. However, if these substitutions were of somatic origin, 
their  even  distribution  all  along  the  chain  would  contrast  sharply  with  the 
clustered organization of substitution mutations. This would imply the existence 
of a particular selective pressure on the COOH-terminal portion of the V~ region, 
which might result in conformational constraints and/or selection by antigen. A 
similar observation has been made for the H chains of anti-GAT antibodies (8). 
Structural  Correlates for  the Public CGAT (or pGAT) Idiotypes.  The structural 
basis of idiotypy has been extensively examined in a  number of systems (for a 
review see reference 33). Apart from the Dex system (34), in which the presence 
of public  idiotypic specificities correlates with  no  more than  two amino acid 
substitutions  in  the  second  hypervariable  region  of the  H  chain,  public  (or 
private) idiotypic specificities generally seem to  correlate with multiple amino 
acid substitutions.  A  detailed  study of the  CGAT  system points  to  the  same 
conclusions,  although  the  system possesses  some  specific  features.  The  most 
interesting aspect is that the CGAT (or pGAT) idiotypic specificities are found 
in all strains of mice that produce anti-GAT antibodies, even though the expres- 
sion of this repertoire may require in certain strains the attachment of the GAT 
random copolymer onto a  protein carrier (1).  Because of this conservation, it 
was proposed that these specificities could be considered as germline markers (1, 
3, 6). The close relatedness of the V regions within each of the CGAT  +, GAT- 
specific VH (7) and V~ (this paper) families certainly supports this view. It seems, 
however, that these markers cannot be merely associated to a single VH-V~ gene 
product pair, since several, although few, genes are necessary to account for the 
expression  of the  entire  CGAT  + repertoire.  At  least  two  VH  genes,  one  in 
BALB/c (7),  one in C57BL/6  (8), and two or three V~ genes (this paper) seem 
to be a minimum number so far. Since the expression of these public idiotopes 
clearly depends upon H-L interactions (4), one must consider that either similar 
three-dimensional determinants may result from slightly different amino acid 
sequences,  or  that  they  may  be  contributed  to  by  stretches  that  are  highly 
conserved between  the  different chains.  In  this  regard,  the  situation  is  not 
symmetrical when the H and the L chains are considered. The evidence presented 
in this article clearly points to the high degree of homology that exists between 
the chains expressed by different strains, even though some strain-specific poly- 
morphism  may  be  present.  By  contrast,  differences were  more  pronounced 
whenever H chains pertaining to discrete strains were analyzed. This was clearly 
the case for the F17 (8)  H  chain, as compared with the BALB/c counterparts TONNELLE ET AL.  1425 
(7).  This observation might indicate that the L chain plays a  major role in the 
constitution of the idiotope per se, although the necessity of H-L interaction also 
clearly points to some participation of the H chain in the expression of idiotypic 
specificities. Wherever the amino acid residues implicated in the expression of 
the CGAT epitopes are to be found, it may be observed that maximal sequence 
conservation lies in the first part of both the H  (between residues 1 and 54; see 
reference 7) and L  (between residues 1 and somewhere in the middle of FR3; 
this paper) chains. The final answer will ultimately rely on the precise analysis of 
the three-dimensional structure of several monoclonal anti-GAT antibodies. The 
possibility of forming similar idiotypic (or more generally antigenic) determinants 
with interacting stretches of complementary H and L chains that are homologous 
but far from identical is certainly gaining more and more supporting evidence. 
Summary 
A large proportion of (Glu  6° Ala  s° Tyrl°)n (GAT)-specific antibodies expresses 
public idiotypic specificities, termed CGAT (or pGAT), that require the presence 
of both the heavy and the light chains in order to be expressed. We report in 
this paper the complete sequence of eight V, regions pertaining to eight anti- 
GAT monoclonal antibodies derived from three strains of mice: BALB/c, DBA/ 
2, and C57BL/6. The methodology used a combination of NH~-terminal amino 
acid and mRNA nucleotide sequencing. All eight sequences analyzed, although 
highly homologous and all pertaining to the same V~I subgroup, allowed defi- 
nition of three germline genes that are likely to be present in all three strains of 
mice and also in  NZB.  It seems likely, however, that any given strain may not 
necessarily use all three genes for making anti-GAT antibodies. The search for 
structural correlates of idiotypes could not be framed in a  simple picture, but 
our  data  suggest  that  similar  idiotopes  may result  from different interacting 
primary structures, leading to structural homologies that should be visualized at 
the three-dimensional level. 
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